Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics

References

• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• SongFAltmanDGGlennyAMDeeksJJValidity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analysesBMJ2003326738747212609941
   PubMed Web of Science ®Google Scholar
• GlennyAMAltmanDGSongFIndirect comparisons of competing interventionsHealth Technol Assess2005926iiiiv
   Web of Science ®Google Scholar
• SongFLokeYKWalshTGlennyAMEastwoodAJAltmanDGMethodological problems in the use of indirect comparisons for evaluating healthcare interventions: Survey of published systematic reviewsBMJ2009338b114719346285
   PubMed Web of Science ®Google Scholar
• LumleyTNetwork meta-analysis for indirect treatment comparisonsStat Med200221162313232412210616
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• CaldwellDMAdesAEHigginsJPSimultaneous comparison of multiple treatments: Combining direct and indirect evidenceBMJ2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• AshbyDBayesian statistics in medicine: A 25 year reviewStat Med200625213589363116947924
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• PalandriFIacobucciIMartinelliGLong-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CMLJ Clin Oncol200826110611118165644
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFGattermannNNilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceBlood2007110103540354617715389
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900
   PubMed Web of Science ®Google Scholar
• BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia NetBlood200610861809182016709930
   PubMed Web of Science ®Google Scholar
• HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFBhallaKNilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 studyBlood2009112111112
   Web of Science ®Google Scholar
• KantarjianHGilesFBhallaKNilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 studyHaematologica200994254255
   Web of Science ®Google Scholar
• HughesTSaglioGBranfordSImpact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseJ Clin Oncol200927254204421019652056
   PubMed Web of Science ®Google Scholar
• MullerMCCortesJKimDWDasatinib efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutationsASH Annual Meeting Abstracts200811211449
   Google Scholar
• HochhausAKimDWMartinelliGNilotinib efficacy according to baseline BCR-ABL mutations in patients with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP)ASH Annual Meeting Abstracts2008112113216
   Google Scholar
• GartlehnerGMooreCGDirect versus indirect comparisons: A summary of the evidenceInt J Technol Assess Health Care200824217017718400120
   PubMed Web of Science ®Google Scholar
• SongFHarveyILilfordRAdjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventionsJ Clin Epidemiol200861545546318394538
   PubMed Web of Science ®Google Scholar
• AdesAESculpherMSuttonABayesian methods for evidence synthesis in cost-effectiveness analysisPharmacoeconomics200624111916445299
   PubMed Web of Science ®Google Scholar
• JansenJPCrawfordBBergmanGStamWBayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisonsValue Health200811595696418489499
   PubMed Web of Science ®Google Scholar
• CooperNJSuttonAJAbramsKRDecision analytical economic modelling within a Bayesian framework: Application to prophylactic antibiotics use for caesarean sectionStat Methods Med Res200211649151212516986
   PubMed Web of Science ®Google Scholar
• CooperNJSuttonAJAbramsKRTurnerDWailooAComprehensive decision analytical modelling in economic evaluation: A Bayesian approachHealth Econ200413320322614981647
   PubMed Web of Science ®Google Scholar
• LogmanJStephensJHeegBComparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infectionsCurr Med Res Opin20102671565157820429820
   PubMed Web of Science ®Google Scholar
• TreurMJMcCrackenFHeegBEfficacy of recombinant activated factor VII vs activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: A Bayesian meta-regressionHaemophilia200915242043619335751
   PubMed Web of Science ®Google Scholar
• JansenFHLesaffreEPenaliLKZatteraMJDie-KakouHBissagneneEAssessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysisAm J Trop Med Hyg20077761005100918165512
   PubMed Web of Science ®Google Scholar
• SungLBeyeneJHaydenJNathanPCLangeBTomlinsonGAA Bayesian meta-analysis of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in children with cancerAm J Epidemiol2006163981181716554346
   PubMed Web of Science ®Google Scholar
• BabapulleMNJosephLBelislePBrophyJMEisenbergMJA hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stentsLancet2004364943458359115313358
   PubMed Web of Science ®Google Scholar
• AfilaloJDuqueGSteeleRJukemaJWde CraenAJEisenbergMJStatins for secondary prevention in elderly patients: A hierarchical Bayesian meta-analysisJ Am Coll Cardiol2008511374518174034
   PubMed Web of Science ®Google Scholar
• OrrRKThe impact of prophylactic axillary node dissection on breast cancer survival – a Bayesian meta-analysisAnn Surg Oncol19996110911610030423
   PubMed Web of Science ®Google Scholar
• LunnDJThomasABestNSpiegelhalterDWinBUGS – a Bayesian modelling framework: Concepts, structure, and extensibilityStat Comput200010325337
   Web of Science ®Google Scholar